DALLAS, TX — December 9th, 2022 — Stonegate Healthcare has published a new report on Retinitis Pigmentosa (RP) and the pipeline of products in development. The report follows a recent webinar with ophthalmology experts, including a leading researcher and physician, Christine Kay, M.D., Vitreoretinal surgeon and IRD specialist at Vitreoretinal Associates, Eric Daniels, M.D., Chief Development Officer of Kiora Pharmaceuticals (NASDAQ: KPRX) and Ben Shaberman from the Foundation Fighting Blindness.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Retinitis Pigmentosa (RP) is the leading cause of visual disability and blindness in patients under 60.
- Gene therapies, while promising, are limited in their application by disease stage and genetic mutation.
- Small molecule photoswitches conversely hold potential to treat mid- to late-stage RP as a stand-alone drug or in combination with gene therapies.
Stonegate Capital Partners is a leading advisory firm founded in 1972. We specialize in capital markets advisory with a focus on institutional investor outreach for public and private companies. Our affiliate, Stonegate Capital Markets (Member FINRA/SIPC) provides a full spectrum of investment banking services and equity research.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
Distributed by: Reportable, Inc.
